New Delhi: The safety trail of mycobacterial w (Mw) drug has been completed but its actual trial will be conducted on 40 patients in PGI Chandigarh and AIIMS-Delhi and Bhopal, said Dr Jagat Ram, Director of PGIMER, Chandigarh on Sunday.
Mycobacterium w, originally developed as an immunomodulator for leprosy, acts through the toll-like receptor pathway and enhances host-T cell responses. “The safety trial of ‘Mw vaccine’ drug has been completed. But its actual trial will be conducted on 40 patients in PGI Chandigarh, AIIMS-Delhi and AIIMS Bhopal,” he said.
The safety trial of ‘Mw vaccine’ drug has been completed. But its actual trial will be conducted on 40 patients in PGI Chandigarh, AIIMS-Delhi and AIIMS Bhopal: Dr Jagat Ram, Director PGIMER, Chandigarh#COVID19 pic.twitter.com/NVHlL5e62o
— ANI (@ANI) May 3, 2020
A study is being conducted by PGIMER-Chandigarh, AIIMS-Delhi, and AIIMS-Bhopal to analyse the use of Mw — heat-killed mycobacterium indicus pranii — as an adjunct to the treatment of critically ill COVID-19 patients.
In a recently concluded multi-centre trial, the PGIMER found that Mw reduces mortality in ICU patients with severe sepsis and it can potentially decrease the cytokine storm seen in patients with COVID-19, and may thus be of potential benefit in managing these patients and decreasing mortality. (ANI)